Hefei Lifeon Pharmaceutical Co Ltd (003020) - Net Assets
Based on the latest financial reports, Hefei Lifeon Pharmaceutical Co Ltd (003020) has net assets worth CN¥1.95 Billion CNY (≈ $284.68 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.60 Billion ≈ $380.12 Million USD) and total liabilities (CN¥652.24 Million ≈ $95.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 003020 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.95 Billion |
| % of Total Assets | 74.89% |
| Annual Growth Rate | 24.2% |
| 5-Year Change | 62.91% |
| 10-Year Change | 787.38% |
| Growth Volatility | 24.63 |
Hefei Lifeon Pharmaceutical Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Hefei Lifeon Pharmaceutical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Hefei Lifeon Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual net assets of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2024. For live valuation and market cap data, see Hefei Lifeon Pharmaceutical Co Ltd (003020) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.91 Billion ≈ $279.87 Million |
+2.09% |
| 2023-12-31 | CN¥1.87 Billion ≈ $274.15 Million |
+26.57% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.60 Million |
+13.52% |
| 2021-12-31 | CN¥1.30 Billion ≈ $190.80 Million |
+11.07% |
| 2020-12-31 | CN¥1.17 Billion ≈ $171.79 Million |
+98.98% |
| 2019-12-31 | CN¥590.00 Million ≈ $86.34 Million |
+16.67% |
| 2018-12-31 | CN¥505.70 Million ≈ $74.00 Million |
+39.81% |
| 2017-12-31 | CN¥361.71 Million ≈ $52.93 Million |
+21.34% |
| 2016-12-31 | CN¥298.09 Million ≈ $43.62 Million |
+38.31% |
| 2014-12-31 | CN¥215.53 Million ≈ $31.54 Million |
+21.85% |
| 2013-12-31 | CN¥176.88 Million ≈ $25.88 Million |
+24.59% |
| 2012-12-31 | CN¥141.96 Million ≈ $20.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hefei Lifeon Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1409.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥940.55 Million | 54.12% |
| Common Stock | CN¥191.57 Million | 11.02% |
| Other Components | CN¥605.76 Million | 34.86% |
| Total Equity | CN¥1.74 Billion | 100.00% |
Hefei Lifeon Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hefei Lifeon Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vivakor Inc
NASDAQ:VIVK
|
$632.67 Million |
|
Ningbo Bohui Chemical Technology
SHE:300839
|
$632.76 Million |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
$632.85 Million |
|
Leong Hup International Berhad
KLSE:6633
|
$633.07 Million |
|
Xinjiang Ba Yi Iron & Steel Co Ltd
SHG:600581
|
$632.56 Million |
|
EirGenix
TWO:6589
|
$632.48 Million |
|
APG SGA SA
SW:APGN
|
$632.38 Million |
|
Shanghai Yimin Commerce Group Co Ltd
SHG:600824
|
$632.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hefei Lifeon Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,685,526,341 to 1,737,886,950, a change of 52,360,609 (3.1%).
- Net income of 160,597,318 contributed positively to equity growth.
- Dividend payments of 80,933,353 reduced retained earnings.
- Share repurchases of 2,951,567 reduced equity.
- Other factors decreased equity by 24,351,789.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥160.60 Million | +9.24% |
| Dividends Paid | CN¥80.93 Million | -4.66% |
| Share Repurchases | CN¥2.95 Million | -0.17% |
| Other Changes | CN¥-24.35 Million | -1.4% |
| Total Change | CN¥- | 3.11% |
Book Value vs Market Value Analysis
This analysis compares Hefei Lifeon Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.80x to 2.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.28 | CN¥22.73 | x |
| 2013-12-31 | CN¥1.59 | CN¥22.73 | x |
| 2014-12-31 | CN¥1.98 | CN¥22.73 | x |
| 2016-12-31 | CN¥2.22 | CN¥22.73 | x |
| 2017-12-31 | CN¥2.69 | CN¥22.73 | x |
| 2018-12-31 | CN¥3.73 | CN¥22.73 | x |
| 2019-12-31 | CN¥4.18 | CN¥22.73 | x |
| 2020-12-31 | CN¥8.31 | CN¥22.73 | x |
| 2021-12-31 | CN¥6.94 | CN¥22.73 | x |
| 2022-12-31 | CN¥7.84 | CN¥22.73 | x |
| 2023-12-31 | CN¥8.77 | CN¥22.73 | x |
| 2024-12-31 | CN¥9.09 | CN¥22.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hefei Lifeon Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.24%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.58%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.49x
- Recent ROE (9.24%) is below the historical average (18.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 25.95% | 5.00% | 2.04x | 2.54x | CN¥22.56 Million |
| 2013 | 26.34% | 5.36% | 1.97x | 2.50x | CN¥29.17 Million |
| 2014 | 24.56% | 5.59% | 2.02x | 2.17x | CN¥31.91 Million |
| 2016 | 22.63% | 6.56% | 1.88x | 1.84x | CN¥37.65 Million |
| 2017 | 21.24% | 6.59% | 1.90x | 1.69x | CN¥40.65 Million |
| 2018 | 18.13% | 6.43% | 1.85x | 1.52x | CN¥41.09 Million |
| 2019 | 17.82% | 6.37% | 1.85x | 1.51x | CN¥46.14 Million |
| 2020 | 11.51% | 7.13% | 1.23x | 1.31x | CN¥17.72 Million |
| 2021 | 13.21% | 7.58% | 1.36x | 1.28x | CN¥41.84 Million |
| 2022 | 14.14% | 8.11% | 1.22x | 1.43x | CN¥61.23 Million |
| 2023 | 13.45% | 11.93% | 0.77x | 1.47x | CN¥58.12 Million |
| 2024 | 9.24% | 10.58% | 0.59x | 1.49x | CN¥-13.19 Million |
Industry Comparison
This section compares Hefei Lifeon Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hefei Lifeon Pharmaceutical Co Ltd (003020) | CN¥1.95 Billion | 25.95% | 0.34x | $632.57 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethy… Read more